BioSpace News Archive

We doubled our total revenues to nearly $200 million in 2023 and ended the year with a robust fourth quarter total revenue of $58 million

REGENXBIO Inc. (Nasdaq: RGNX) today announced financial results for the fourth quarter and full year ended December 31, 2023, and recent operational highlights, including progress on the strategic pipeline prioritization and corporate restructuring intended to significantly reduce operating expenses and support meaningful value generation from the Company’s strong pipeline of AAV Therapeutics.

Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the fourth quarter and the full-year ended December 31, 2023.

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the fourth quarter and full year ended December 31, 2023.

Masimo (Nasdaq: MASI) today announced its financial results for the fourth quarter and full-year ended December 30, 2023.

Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for axatilimab, an anti-CSF-1R antibody, for the treatment of chronic graft-versus-host disease (GVHD) after failure of at least two prior lines of systemic therapy.

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, announced that management will be participating in three upcoming investor conferences.

Protagonist Therapeutics (Nasdaq:PTGX) (“Protagonist” or “the Company”) today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.

Rapid Micro Biosystems, Inc., an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, announced that the Company will participate in the following investor conferences.

Tenaya Therapeutics, Inc. announced that company management will participate in TD Cowen’s 44th Annual Health Care Conference and Leerink Partners Global Biopharma Conference 2024.